Food and nutraceutical expert Beneo has teamed up with Wacker to launch 2’-Fucosyllactose X(2’-FL), a human milk oligosaccharide (HMO) ingredient, globally.
The early-life nutrition ingredient will initially be available to the European market, being produced through precision fermentation by Wacker and commercialised by Beneo.
According to Beneo, 2’-Fucosyllactose X(2’-FL) is the predominant and most extensively studied HMO, and is commonly considered the "gold standard" in infant nutrition.
The ingredient is the first result of Beneo and Wacker's global partnership, which focuses on expanding each company's footprint in the early life nutrition space.
The launch of this HMO ingredient comes at a time when the global demand for HMOs is forecast to grow significantly, with Spherial Insights estimating that USD $180m in 2022 to almost $900m by 2032, reflecting a compound annual growth rate (CAGR) of more than 17 percent.1
“The launch of 2’-FL and the associated addition of HMOs to Beneo’s established and well recognised portfolio of scientifically proven prebiotics is strategic," noted Olivier Roques, CEO at Beneo.
"HMOs provide promising opportunities for the infant nutrition market, allowing manufacturers to create highly effective functional combinations."
"By combining our expertise and production track record with Beneo's thorough market understanding, we hope to meet the demands of customers in the infant nutrition sector globally," added Wacker Biosolutions' President, Mathias Widermann.
Reference
1 https://www.globenewswire.com/news-release/2023/12/06/2791573/0/en/Global-Human-Milk-Oligosaccharides-HMO-Market-Size-To-Exceed-USD-896-91-Million-By-2032-CAGR-of-17-34.html
